

MAY 10 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ferrara et al. Examiner: Unassigned
Serial No.: 10/692,299 Group Art Unit: 1644
Filed: October 22, 2003 Docket: 11669.0139USC1
Confirmation No.: Unassigned Notice of Allow. Date:

Due Date:

Title: EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408487911 US
Date of Deposit: May 10, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Name: Lynda Kraft

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 0 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By:

Name: Denise Kettelberger

Reg. No.: 33,924

DMK:EED:lek

(PTO TRANSMITTAL - GENERAL)



Unassigned

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ferrara et al.	Examiner:	Unassigned
Serial No.:	10/692,299	Group Art Unit:	1644
Filed:	October 22, 2003	Docket No.:	11669.0139USC1
Title:	EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408487911 US

Date of Deposit: May 6, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop Patent Application, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Name: Lynnda Kraft

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(d), a copy of each document or other information listed on the enclosed Form 1449 is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/886,242 filed on June 20, 2001.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903

Date: _____

5 May 2004

Denise M. Kettelberger

Denise M. Kettelberger, Ph.D.
Reg. No. 33,924
DMK:lek

23552

PATENT TRADEMARK OFFICE

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.139USC1


Application Number:

10/692,299

Applicant: Ferrara et al.

Filing Date: October 22,
2003

Group Art Unit:



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/06550	11.02.99	PCT				
	WO 99/63088	09.12.99	PCT				
	WO 00/52022	08.09.00	PCT				
	WO 00/53753	14.09.00	PCT				
	WO 00/70049	23.11.00	PCT				
	WO 00/73454	07.12.00	PCT				
	WO 00/75327	14.12.00	PCT				
	WO 01/36465	25.05.01	PCT				
	WO 01/40466	07.06.01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Aird, W.C. et al., 1997, <i>J. Cell Biol.</i> 138:1117-1124 "Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment"
		Aravind, L. and Koonin, E.V., 1998, <i>Curr. Biol.</i> 8:477-478 "A colipase fold in the carboxy-terminal domain of the Wnt antagonists- the Dickkopfs"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.139USC1

Application Number:

10/692,299

Applicant: Ferrara et al.

Filing Date: October 22,
2003


Group Art Unit:

	Arbiser, J.L. et al., 1997, <i>Proc. Natl. Acad. Sci. USA</i> , 94:861-866 "Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways"
	Attwood et al., Oct 2000, <i>Science</i> 290(5491): 417-473 "The babel of bioinformatics"
	Basset, D.L., 1943, <i>Am. J. Anat.</i> , 73:251-278 "The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle"
	Boisbouvier, J. et al., 1998, <i>J. Mol. Biol.</i> 283: 205-219 "A structural homologue of colipase in black mamba venom revealed by NMR floating disulphide bridge analysis"
	Carmeliet, P., 2000, <i>Nature Medicine</i> , 6:389-395 "Mechanisms of angiogenesis and arteriogenesis"
	Collin, O. & Bergh A., 1996, <i>Int. J. Androl.</i> , 19:221-228 "Leydig cells secrete factors which increase vascular permeability and endothelial cell proliferation"
	Dellian, M. et al., 1996, <i>Am. J. Pathology</i> , 149:59-71 "Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment"
	Esser, S. et al., 1998, <i>J. Cell. Biol.</i> , 140:947-959 "Vascular endothelial growth factor induces endothelial fenestrations in vitro" (1998)
	Ferrara, N. & Alitalo, 1999, <i>Nature Medicine</i> , 5:1359-1364 "K. Clinical applications of angiogenic growth factors and their inhibitors"
	Ferrara, N. et al., 1998, <i>Nature Medicine</i> , 4:336-340 "Vascular endothelial growth factor is essential for corpus luteum angiogenesis"
	Ferrara, N., 2000, <i>Curr. Opin. Biotech</i> 11: 617-624 "VEGF: an update on biological and therapeutic aspects"
	Fogarty et al., 2002, <i>The Scientist</i> , 16(16):33
	Fraser et al., 2000, <i>Endocrinology</i> , 141(3):995-1000 "Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor"
	Gille, H. et al., 2001, <i>J. Biol. Chem.</i> , 276:3222-3230 "Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants"
	Glinka, A. et al., 1998, <i>Nature</i> , 391:357-362 "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction"
	Goldziher, J.W. & Green, J.A., 1962, <i>J. Clin. Endocrinol. Meta.</i> 22:325-332 "The polycystic ovary. I. Clinical and histologic features"

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* 	INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11669.139USC1	Application Number: 10/692,299
			Applicant: Ferrara et al.	
			Filing Date: October 22, 2003	Group Art Unit:

		Gospodarowicz et al., 1984, <i>J. Cell. Biol.</i> , 99:947-961 "Comparison of the Ability of Basement Membranes Produced by Corneal Endothelial and Mouse-derived Endodermal PF-HR-9 Cells to Support the Proliferation and Differentiation of Bovine Kidney Tubule Epithelial Cells in Vitro"
		Joubert, F.J. & Strydom, D.J., 1980, <i>Hoppe-Seylers Zeitschrift fur Physiologische Chemie</i> , 361:1787-1794 "Snake venom. The amino acid sequence of protein A from <i>Dendroaspis polylepis polytepis</i> (black mamba) veno"
		Klagsburn, M., 1992, <i>Semin. Cancer Biol.</i> , 3:81-87 "Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions"
		Krupnik, V.E. et al., 1999, <i>Gene</i> , 238:301-313 "Functional and structural diversity of the human Dickkopf gene family"
		LeCouter, J. et al., 2001, <i>Nature</i> , 412(6850):877-884 "Identification of an angiogenic mitogen selective for endocrine gland endothelium"
		Leung et al., 1989, <i>Science</i> , 246:1306-1309 "Vascular endothelial growth factor is a secreted angiogenic mitogen"
		Lind et al., 1995, <i>APMIS</i> , 103:140-146 "Chemotaxis of buma osteoblasts"
		Melton, D. A. et al., 1984, <i>Nucleic Acids Res.</i> , 12:7035-7056 "Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter"
		Mesiano et al., 1993, <i>J. Clin. Endocrinol. Metab.</i> 76:968-976 "Mitogenic Action, Regulation, and Localization of Insulin-Like Growth Factors in the Human Fetal Adrenal Gland"
		Mueller et al., 1995, <i>Eur. J. Immunol.</i> , 25:1744-1746 "Cloning of ATAC, an activation-induced chemokine-related molecule exclusively expressed in CD7+ T lymphocytes"
		Ngo et al., in <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , 1994, Merz et al., (ed.), Birkhauser, Boston, MA, 443 and 492-495
		Palade, G.E. et al., 1979, <i>Acta Physiol. Scand. Suppl.</i> , 463:11-32 "Structural aspects of the permeability of the microvascular endothelium"
		Pettersen, A. et al., 2000, <i>Lab. Invest.</i> 80:99-115 "Heterogeneity of the angiogenic response induced in different normal tissues by vascular permeability factor/vascular endothelial growth factor"
		Phillips, H.S. et al., 1990, <i>Science</i> 250:290-294 "Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons"
		Phillips et al., 1990, <i>Endocrinology</i> , 127:965-967 "Vascular endothelial growth factor is expressed in rat corpus luteum"

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	


INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.139USC1

Application Number:

10/692,299

Applicant: Ferrara et al.

Filing Date: October 22,
2003

Group Art Unit:

		Ravindranath et al., 1992, <i>Endocrinology</i> , 131(1):254-260 "Vascular Endothelial Growth Factor Messenger Ribonucleic Acid Expression in the Primate Ovary"
		Roberts and Palade, 1997, <i>Cancer Res.</i> , 57:765-772 "Host Microvasculature Influence on Tumor Vascular Morphology and Endothelial Gene Expression"
		Ryan A.M. et al., 1999, <i>Toxicol. Pathol.</i> 27:78-86 "Preclinical safety evaluation of rhuMabVEGF, an Antiangiogenic humanized monoclonal antibody"
		Schweitz et al., 1999, <i>FEBS Lett.</i> 461:183-188 "MIT(1), a black mamba toxin with a new and highly potent activity on intestinal contraction"
		Semenza, G.L., 2000, <i>J. Appl. Physiol.</i> 88:1474-1480 "HIF-1: mediator of physiological and pathophysiological response to hypoxia"
		Simionescu, N. & Simionescu, M., 1988, ed. Weiss, L., Urban & Schwarzenberg, Baltimore 355-398 "The Cardiovascular System"
		Soker et al., 1998, <i>Cell</i> 92:735-745 "Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor"
		Skolnick et al., Jan 2000, <i>Trends in Biotech.</i> 18(1):34-39 "From genes to protein structure and function: novel applications of computational approaches in the genomic era"
		Stewart and Wiley, 1981, <i>Dev. Biol.</i> 84:183-192 "Developing Nervous Tissue Induces Formation of Blood-Brain Barrier Characteristics in invading Endothelial Cells: A Study Using Quail-Chick Transplantation Chimeras"
		Taub et al., 1995, <i>J. Clin. Invest.</i> 95:1370-1376 "T Lymphocyte Recruitment by Interleukin-8 (IL-8)"
		Van Tilbeurgh et al., 1992, <i>Nature</i> , 359:159-162 "Structure of the pancreatic lipase-procolipase complex"
		Wechselberger, C. et al., 1999, <i>FEBS Lett.</i> 462:177-181 "The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes"
		Zetter, B.R., 1980, <i>Nature</i> , 285:41-43 "Migration of capillary endothelial cells is stimulated by tumour-derived factors"

23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.